#最小單位貼紙

Suppressing postpartum lactation in women unable or not desiring to breast-feed or when breast-feeding is considered undesirable on medical grounds.

Cabergoline is a long-acting, selective dopamine receptor agonist, exhibiting high affinity for D2 receptors and low affinity for D1, alpha 1- and alpha 2-adrenergic, and serotonin (5-HT1 and 5-HT2) receptors. Cabergoline inhibits the synthesis and release of prolactin from the anterior pituitary by directly stimulating the D2 receptors of the pituitary lactotrophs in a dose-related fashion.

Initial Response: (hyperprolactinemia) 3 hours, (lactation inhibition) 24 hours; Protein Binding: 40% - 42%; Metabolism: hepatic; Excretion: (fecal) 60%, (renal) 22%, 4% unchanged; Elimination half-life: 63 - 69 hours.

Hypersensitivity to ergot derivatives, uncontrolled hypertension; History of pulmonary, pericardial, or retroperitoneal fibrotic disorders; active or history of cardiac valvular disorder

B [FDA]

Evidence suggests this drug may alter milk production or composition. If an alternative to this drug is not prescribed, monitor the infant for adverse effects and/or adequate milk intake.

Nausea(27% to 29%), headache(9% to 30%), dizziness(9% to 17%), constipation(7% to 10%), fatigue(5% to 10%), hot flushes(3%).

Lactation suppression: 1 mg as a single dose on the first day after delivery; Hyperprolactinemia: initial, 0.25 mg ORALLY twice weekly, increase by 0.25 mg twice weekly at 4 wk intervals; MAX 1 mg twice weekly.